Zahava Vadasz1, Tova Rainis2, Afif Nakhleh1, Tharwat Haj1, Jacob Bejar3, Katty Halasz1, Elias Toubi1. 1. Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Technion, Haifa, Israel. 2. Division of Gastroenterology, Bnai Zion Medical Center, Technion, Haifa, Israel. 3. Department of Pathology, Bnai Zion Medical Center, Technion, Haifa, Israel.
Abstract
BACKGROUND AND AIMS: Immune semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. We aim to assess the possible involvement of semaphorin3A (sema3A) and 4A (sema4A) in peripheral immune responses and bowel tissue inflammation of patients suffering from Crohn's disease (CD) and ulcerative colitis (UC). PATIENTS AND METHODS: Twenty-seven CD patients and 10 UC patients were studied and compared to 10 patients followed for acute diverticulitis (disease control) and 12 healthy individuals. All were evaluated for sema3A expression on T regulatory cells (Tregs), serum levels of sema3A and sema4A, and tissue expression of sema3A and sema4A in bowel biopsies. RESULTS: The percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ± 14.49%) and active UC (49.8% ± 16.45%) was significantly lower when compared to that of healthy controls (88.7% ± 3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69 ± 1 .48 ng\ml for CD, 5.26 ± 1.23 ng/ml for UC patients vs 9.74 ± 2.73 ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals. CONCLUSIONS: Altered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.
BACKGROUND AND AIMS: Immune semaphorins are a large family of proteins involved in the pathogenesis of inflammatory diseases through the regulation of immune homeostasis and tissue inflammation. We aim to assess the possible involvement of semaphorin3A (sema3A) and 4A (sema4A) in peripheral immune responses and bowel tissue inflammation of patients suffering from Crohn's disease (CD) and ulcerative colitis (UC). PATIENTS AND METHODS: Twenty-seven CDpatients and 10 UC patients were studied and compared to 10 patients followed for acute diverticulitis (disease control) and 12 healthy individuals. All were evaluated for sema3A expression on T regulatory cells (Tregs), serum levels of sema3A and sema4A, and tissue expression of sema3A and sema4A in bowel biopsies. RESULTS: The percentage (%) of T regulatory cells (Tregs) expressing sema3A in patients with active CD (64.5% ± 14.49%) and active UC (49.8% ± 16.45%) was significantly lower when compared to that of healthy controls (88.7% ± 3.6%, p< 0.001 and p< 0.0001, respectively). This expression was seen to be in negative correlation with CD activity. Serum levels of Sema4A were significantly lower in patients with CD and UC when compared to that of controls (5.69 ± 1 .48 ng\ml for CD, 5.26 ± 1.23 ng/ml for UC patients vs 9.74 ± 2.73 ng/ml for normal controls, P<0.001). Sema4A was highly expressed in lymphocytes of the lamina propria of CD and UC patients but absent in patients with diverticulitis or in normal individuals. CONCLUSIONS: Altered % of Tregs expressing sema3A in patients with inflammatory bowel diseases (IBD) is partially responsible for their failure in preventing CD4+ effector T cell induced inflammation in IBD in peripheral blood. The increased expression of sema4A in bowel biopsies from CD and UC patients is suggestive of its central role in regulating local tissue inflammation in the bowel.
Authors: David T Okou; Kajari Mondal; William A Faubion; Lisa J Kobrynski; Lee A Denson; Jennifer G Mulle; Dhanya Ramachandran; Yuning Xiong; Phyllis Svingen; Viren Patel; Promita Bose; Jon P Waters; Sampath Prahalad; David J Cutler; Michael E Zwick; Subra Kugathasan Journal: J Pediatr Gastroenterol Nutr Date: 2014-05 Impact factor: 2.839
Authors: Aito Ueno; Humberto Jijon; Ronald Chan; Kim Ford; Christina Hirota; Gilaad G Kaplan; Paul L Beck; Marietta Iacucci; Miriam Fort Gasia; Herman W Barkema; Remo Panaccione; Subrata Ghosh Journal: Inflamm Bowel Dis Date: 2013-11 Impact factor: 5.325
Authors: Wasif N Khan; Jacqueline A Wright; Eden Kleiman; Justin C Boucher; Iris Castro; Emily S Clark Journal: Immunol Res Date: 2013-12 Impact factor: 2.829
Authors: Alessandra Geremia; Paolo Biancheri; Philip Allan; Gino R Corazza; Antonio Di Sabatino Journal: Autoimmun Rev Date: 2013-06-15 Impact factor: 9.754
Authors: Greg M Delgoffe; Seng-Ryong Woo; Meghan E Turnis; David M Gravano; Cliff Guy; Abigail E Overacre; Matthew L Bettini; Peter Vogel; David Finkelstein; Jody Bonnevier; Creg J Workman; Dario A A Vignali Journal: Nature Date: 2013-08-04 Impact factor: 49.962
Authors: You-Jung Ha; Dong Woo Han; Ji Hyoun Kim; Sang Wan Chung; Eun Ha Kang; Yeong Wook Song; Yun Jong Lee Journal: Dis Markers Date: 2018-11-14 Impact factor: 3.434
Authors: Ying Lin; Quan Xing; Wei Qin; Mary Anne Sampaio de Melo; Rui Zou; Meng Xu; Xiaolei Zhang; Hockin H K Xu; Zhengmei Lin Journal: Biomed Res Int Date: 2017-12-31 Impact factor: 3.411